Covid-19: the call for projects to manufacture treatments “will ensure health autonomy”, estimates drug companies

Covid-19: the call for projects to manufacture treatments “will ensure health autonomy”, estimates drug companies

Frédéric Collet, president of LEEM, the professional organization of drug companies in France, described as “very good news” the launch of a call for projects of 300 million euros to manufacture vaccines and treatments against Covid-19 in France.

A vial of vaccine against Covid-19.  (JOEL SAGET / AFP)

L’call for projects of 300 million euros to manufacture vaccines and treatments against Covid-19 in France, announced on franceinfo / France Inter on Sunday February 7 by the Minister for Industry, Agnès Pannier-Runacher will help to “rebuild all the conditions of attractiveness and competitiveness (in France) and then finally ensure what we are looking for, namely health autonomy“, Assures Frédéric Collet, president of Pharmaceutical companies, the professional organization of drug companies in France.

When asked whether 300 million euros are sufficient, Frédéric Collet stresses that the important thing is “le signal that this sends (…). The successive policies of the past 30 years have helped ensure that we are where we are today. (…) France was the leading manufacturer of industrial medicines at the start of the 2000s, we are now the fourth. We were the first European country in terms of public research, we are now the fourth. So, this policy, this investment, is going in the right direction because it will make it possible to mobilize the conditions to recreate this attractiveness.“, Judge the president of LEEM.

A sector that represents 100,000 jobs

Frédéric Collet also believes that this call for projects shows that “the pharmaceutical business sector is a sector that has emerged from the crisis. We have seen its exceptional mobilization during this pandemic. We were able to get a vaccine out in a year and start the vaccination. It normally takes ten years to do this ”, underlines Frédéric Collet, recalling that the drug sector in France represents more than 260 companies and 100,000 employees.

It is also an attractive sector for the healthcare professions and for new technologies. And then, these are also skilled and regional jobs“, Concludes the president of LEEM.